modified recombinant H7 hemagglutinin influenza vaccine

A modified recombinant H7 hemagglutinin influenza vaccine is a protein subunit vaccine, specifically designed using *recombinant DNA technology* to express a modified version of the hemagglutinin (HA) protein from the H7 subtype of influenza A viruses (such as H7N9)[1][3][4]. The "modified" term usually refers to specific genetic changes (such as amino acid substitutions in HA) intended to improve immunogenicity and large-scale production in cell-based or egg-based vaccine manufacturing[3]. The full-length recombinant H7 HA can be formulated as soluble protein, virus-like particles (VLP), or oligomeric (subviral) particles, all preserving critical epitopes needed to induce protective immune responses in humans and animal models[1]. The mechanism of action is the induction of neutralizing antibodies mainly targeting the H7 HA antigen, granting subtype-specific and, in some cases, cross-protective immunity against H7 influenza viruses[4][1]. Developers of such vaccines include multiple public health organizations and biotechnology companies[3][5]. Indications are prevention of influenza caused by H7 subtype viruses—these are of pandemic concern, especially H7N9[3][1]. Adjuvants may be used to enhance immunogenicity[4].

Other names

rH7 HArH-7 HArH 7 HArecombinant H7 HA vaccinemodified recombinant H7 hemagglutinin vaccine